Clinicopathological and Molecular Changes Induced by Neoadjuvant Chemotherapy and Endocrine Therapy in HR-Positive/HER2-Low and HR-Positive/HER2-0 Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer
ESMO Open 2024 Jun 28;9(7)103619, F Schettini, S Nucera, F Brasó-Maristany, I De Santo, T Pascual, M Bergamino, P Galván, B Conte, E Seguí, I García Fructuoso, R Gómez Bravo, P Rivera, AB Rodríguez, O Martínez-Sáez, S Ganau, E Sanfeliu, B González-Farre, MJ Vidal Losada, B Adamo, I Cebrecos, E Mension, G Oses, P Jares, S Vidal-Sicart, M Mollà, M Muñoz, A PratFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.